C WorldWide Group Holding A S Cuts Stock Position in Natera, Inc. $NTRA

C WorldWide Group Holding A S decreased its holdings in shares of Natera, Inc. (NASDAQ:NTRA) by 17.5% during the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 165,000 shares of the medical research company’s stock after selling 35,000 shares during the quarter. C WorldWide Group Holding A S’s holdings in Natera were worth $26,560,000 as of its most recent filing with the Securities and Exchange Commission.

Several other large investors have also recently added to or reduced their stakes in the stock. BI Asset Management Fondsmaeglerselskab A S raised its position in Natera by 79.8% in the third quarter. BI Asset Management Fondsmaeglerselskab A S now owns 4,139 shares of the medical research company’s stock valued at $666,000 after purchasing an additional 1,837 shares during the period. Envestnet Asset Management Inc. grew its stake in shares of Natera by 10.0% in the third quarter. Envestnet Asset Management Inc. now owns 189,276 shares of the medical research company’s stock valued at $30,468,000 after buying an additional 17,254 shares in the last quarter. Strengthening Families & Communities LLC purchased a new stake in shares of Natera during the 3rd quarter valued at about $688,000. WCM Investment Management LLC lifted its position in Natera by 3.4% during the 3rd quarter. WCM Investment Management LLC now owns 6,686 shares of the medical research company’s stock worth $1,090,000 after acquiring an additional 221 shares in the last quarter. Finally, AXS Investments LLC acquired a new position in Natera during the 3rd quarter worth approximately $69,000. 99.90% of the stock is currently owned by institutional investors and hedge funds.

Natera Stock Performance

NTRA opened at $205.61 on Thursday. The company has a market capitalization of $28.44 billion, a P/E ratio of -89.79 and a beta of 1.64. The company has a 50-day moving average of $234.95 and a 200-day moving average of $195.74. Natera, Inc. has a 1-year low of $125.38 and a 1-year high of $256.36.

Natera (NASDAQ:NTRA) last issued its quarterly earnings results on Friday, November 7th. The medical research company reported ($0.64) EPS for the quarter, missing the consensus estimate of ($0.39) by ($0.25). The company had revenue of $592.18 million for the quarter, compared to the consensus estimate of $514.55 million. Natera had a negative return on equity of 25.07% and a negative net margin of 14.61%.The business’s revenue for the quarter was up 34.7% on a year-over-year basis. During the same period in the previous year, the business posted ($0.26) EPS. As a group, sell-side analysts expect that Natera, Inc. will post -1.49 earnings per share for the current fiscal year.

Insider Transactions at Natera

In other Natera news, CEO Steven Leonard Chapman sold 4,725 shares of the stock in a transaction that occurred on Tuesday, February 3rd. The stock was sold at an average price of $230.77, for a total transaction of $1,090,388.25. Following the transaction, the chief executive officer owned 123,156 shares of the company’s stock, valued at $28,420,710.12. This trade represents a 3.69% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, insider John Fesko sold 3,594 shares of the business’s stock in a transaction that occurred on Tuesday, February 3rd. The shares were sold at an average price of $231.02, for a total value of $830,285.88. Following the completion of the sale, the insider owned 178,081 shares of the company’s stock, valued at $41,140,272.62. This trade represents a 1.98% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last ninety days, insiders have sold 455,899 shares of company stock worth $106,475,440. 5.63% of the stock is owned by corporate insiders.

Natera News Summary

Here are the key news stories impacting Natera this week:

• Positive Sentiment: Natera submitted a Premarket Approval (PMA) to the FDA for Signatera CDx to detect minimal residual disease (MRD) in bladder cancer after positive phase‑3 results — a regulatory win that could create a companion diagnostic revenue stream and improve clinical adoption/reimbursement if approved. Read More.
• Neutral Sentiment: Multiple non‑executive insiders also sold shares this week (Solomon Moshkevich and John Fesko each trimmed small single‑digit percentages of their holdings). These appear to be modest, routine dispositions versus strategic exits but add to selling pressure. Read More.
• Negative Sentiment: CEO Steven Chapman sold 85,299 shares on Feb 2 (~40% reduction in his holding) for a proceeds block of roughly $19.7M — a material insider disposition that investors often view negatively. Read More.
• Negative Sentiment: Additional executive sales this week: CEO Chapman sold another 4,725 shares (Feb 3) and CFO Michael Burkes Brophy sold 6,939 shares (Feb 3), each trimming double‑digit or mid‑single digit ownership percentages — reinforcing near‑term downward pressure on the stock. Read More. Read More.

Wall Street Analysts Forecast Growth

A number of analysts have recently issued reports on the stock. Citigroup initiated coverage on shares of Natera in a research note on Wednesday, January 7th. They set a “buy” rating and a $300.00 price objective on the stock. Wells Fargo & Company lifted their price target on shares of Natera from $190.00 to $205.00 and gave the stock an “equal weight” rating in a research note on Monday, December 15th. Stephens upped their price objective on shares of Natera from $197.00 to $235.00 and gave the company an “overweight” rating in a research report on Thursday, November 13th. Zacks Research upgraded Natera from a “strong sell” rating to a “hold” rating in a research note on Thursday, January 1st. Finally, BNP Paribas Exane upgraded Natera to a “hold” rating and set a $172.00 price target on the stock in a research note on Monday, October 27th. One equities research analyst has rated the stock with a Strong Buy rating, thirteen have issued a Buy rating, three have assigned a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, Natera currently has a consensus rating of “Moderate Buy” and an average price target of $249.20.

Natera Profile

Natera is a global diagnostics company that develops and commercializes cell-free DNA and other genetic testing technologies for clinical applications. The company focuses on three principal areas: reproductive health (including non-invasive prenatal testing and carrier screening), oncology (tumor-informed assays for minimal residual disease and recurrence monitoring), and organ transplantation (cell-free DNA tests to detect allograft injury). Natera combines laboratory testing, proprietary bioinformatics, and clinical reporting to deliver personalized genetic information to clinicians and patients.

Key product offerings include Panorama, a non-invasive prenatal test that screens for fetal chromosomal abnormalities and select single-gene conditions; Horizon carrier screening for inherited conditions; Signatera, a personalized, tumor-informed assay used for detecting minimal residual disease and monitoring treatment response in cancer patients; and Prospera, a donor-derived cell-free DNA test used to assess the risk of organ rejection.